FAGR Aperçu des actions
Fagron NV, une société de préparation pharmaceutique, fournit des soins pharmaceutiques personnalisés aux hôpitaux, aux pharmacies, aux cliniques et aux patients dans le monde entier.
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 1/6 |
| Performances passées | 5/6 |
| Santé financière | 4/6 |
| Dividendes | 2/6 |
Fagron NV Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | €18.58 |
| Plus haut sur 52 semaines | €20.05 |
| Plus bas sur 52 semaines | €16.50 |
| Bêta | 0.27 |
| 1Variation sur 1 mois | 3.45% |
| Variation sur 3 mois | -1.80% |
| Variation sur 1 an | 9.94% |
| 3Variation sur 3 ans | 25.20% |
| Variation sur 5 ans | 6.60% |
| Évolution depuis l'introduction en bourse | 84.51% |
Nouvelles et mises à jour récentes
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Fagron NV (EBR:FAGR)
Oct 07
Fagron NV's (EBR:FAGR) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 07The Returns At Fagron (EBR:FAGR) Aren't Growing
Apr 17Is Fagron (EBR:FAGR) A Risky Investment?
Mar 15Earnings Tell The Story For Fagron NV (EBR:FAGR)
Feb 18Fagron (EBR:FAGR) Seems To Use Debt Quite Sensibly
Aug 11Be Wary Of Fagron (EBR:FAGR) And Its Returns On Capital
Jun 10Fagron (EBR:FAGR) Has Announced That It Will Be Increasing Its Dividend To €0.175
May 12An Intrinsic Calculation For Fagron NV (EBR:FAGR) Suggests It's 30% Undervalued
Apr 20Is Fagron (EBR:FAGR) A Risky Investment?
Apr 02Here's Why Fagron (EBR:FAGR) Can Manage Its Debt Responsibly
Oct 14Return Trends At Fagron (EBR:FAGR) Aren't Appealing
Jun 04Fagron (EBR:FAGR) Is Paying Out A Larger Dividend Than Last Year
May 13Is Fagron (EBR:FAGR) Using Too Much Debt?
Apr 13Slowing Rates Of Return At Fagron (EBR:FAGR) Leave Little Room For Excitement
Feb 16Fagron (EBR:FAGR) Has A Pretty Healthy Balance Sheet
Nov 18Fagron (EBR:FAGR) Is Experiencing Growth In Returns On Capital
Sep 25Are Investors Undervaluing Fagron NV (EBR:FAGR) By 45%?
Aug 30Fagron NV (EBR:FAGR) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 08Is Fagron (EBR:FAGR) A Risky Investment?
Jun 15Fagron NV (EBR:FAGR) Shares Could Be 49% Below Their Intrinsic Value Estimate
May 29The Returns At Fagron (EBR:FAGR) Aren't Growing
May 03Here's Why Fagron (EBR:FAGR) Can Manage Its Debt Responsibly
Mar 08Is Fagron NV (EBR:FAGR) A Smart Choice For Dividend Investors?
Feb 22The Returns At Fagron (EBR:FAGR) Provide Us With Signs Of What's To Come
Jan 31Is Fagron NV (EBR:FAGR) Popular Amongst Institutions?
Jan 14
How Much Does Fagron's (EBR:FAGR) CEO Make?
Dec 27Are Investors Undervaluing Fagron NV (EBR:FAGR) By 25%?
Dec 14Fagron (EBR:FAGR) Seems To Use Debt Quite Sensibly
Nov 30Should You Be Excited About Fagron NV's (EBR:FAGR) 26% Return On Equity?
Nov 17Is Fagron (EBR:FAGR) Using Too Much Debt?
Aug 23Why Fagron NV (EBR:FAGR) Looks Like A Quality Company
Aug 10Should Fagron (EBR:FAGR) Be Disappointed With Their 64% Profit?
Jul 28Will Fagron (EBR:FAGR) Multiply In Value Going Forward?
Jul 14What Kind Of Shareholder Owns Most Fagron NV (EBR:FAGR) Stock?
Jun 30Rendement pour les actionnaires
| FAGR | BE Healthcare | BE Marché | |
|---|---|---|---|
| 7D | -1.7% | -2.1% | -2.0% |
| 1Y | 9.9% | 12.2% | 8.5% |
Rendement vs Industrie: FAGR underperformed the Belgian Healthcare industry which returned 12.3% over the past year.
Rendement vs marché: FAGR exceeded the Belgian Market which returned 8% over the past year.
Volatilité des prix
| FAGR volatility | |
|---|---|
| FAGR Average Weekly Movement | 2.1% |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in BE Market | 6.5% |
| 10% least volatile stocks in BE Market | 2.2% |
Cours de l'action stable: FAGR has not had significant price volatility in the past 3 months compared to the Belgian market.
Volatilité au fil du temps: FAGR's weekly volatility (2%) has been stable over the past year.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1990 | 3,647 | Rafael Padilla | www.fagron.com |
Fagron NV, une société de préparation pharmaceutique, fournit des soins pharmaceutiques personnalisés aux hôpitaux, aux pharmacies, aux cliniques et aux patients dans le monde entier. Elle opère dans trois secteurs : Essentials, Brands et Compounding Services. L'entreprise innove également en matière de concepts, de véhicules et de formulations pour les préparations pharmaceutiques.
Fagron NV Résumé des fondamentaux
| FAGR statistiques fondamentales | |
|---|---|
| Capitalisation boursière | €1.36b |
| Bénéfices(TTM) | €77.94m |
| Recettes(TTM) | €820.76m |
17.4x
Ratio P/E1.7x
Ratio P/SLe site FAGR est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| FAGR compte de résultat (TTM) | |
|---|---|
| Recettes | €820.76m |
| Coût des recettes | €458.22m |
| Marge brute | €362.54m |
| Autres dépenses | €284.61m |
| Les revenus | €77.94m |
Derniers bénéfices déclarés
Jun 30, 2024
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 1.07 |
| Marge brute | 44.17% |
| Marge bénéficiaire nette | 9.50% |
| Ratio dettes/capitaux propres | 69.2% |
Quelles ont été les performances à long terme de FAGR?
Voir les performances historiques et les comparaisons